JP2014503595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503595A5 JP2014503595A5 JP2013551362A JP2013551362A JP2014503595A5 JP 2014503595 A5 JP2014503595 A5 JP 2014503595A5 JP 2013551362 A JP2013551362 A JP 2013551362A JP 2013551362 A JP2013551362 A JP 2013551362A JP 2014503595 A5 JP2014503595 A5 JP 2014503595A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- coor
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000000547 substituted alkyl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- -1 -C 3-6 cycloalkyl Chemical group 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 229940126154 HIV entry inhibitor Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 0 CC(C)(C1CC2)C(**)=CC[C@]1(C)C(CC1)[C@]2(C)[C@@]2(C)[C@]1C(CCC1)[C@@]1(*)CC2 Chemical compound CC(C)(C1CC2)C(**)=CC[C@]1(C)C(CC1)[C@]2(C)[C@@]2(C)[C@]1C(CCC1)[C@@]1(*)CC2 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437893P | 2011-01-31 | 2011-01-31 | |
| US61/437,893 | 2011-01-31 | ||
| PCT/US2012/022852 WO2012106190A1 (en) | 2011-01-31 | 2012-01-27 | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503595A JP2014503595A (ja) | 2014-02-13 |
| JP2014503595A5 true JP2014503595A5 (enExample) | 2015-02-26 |
| JP6001560B2 JP6001560B2 (ja) | 2016-10-05 |
Family
ID=45567147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551362A Active JP6001560B2 (ja) | 2011-01-31 | 2012-01-27 | Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8846647B2 (enExample) |
| EP (1) | EP2670765B1 (enExample) |
| JP (1) | JP6001560B2 (enExample) |
| KR (1) | KR101886467B1 (enExample) |
| CN (1) | CN103429607B (enExample) |
| AR (1) | AR085053A1 (enExample) |
| AU (1) | AU2012212509B2 (enExample) |
| BR (1) | BR112013019419A2 (enExample) |
| CA (1) | CA2826113C (enExample) |
| CL (1) | CL2013002185A1 (enExample) |
| CO (1) | CO6751275A2 (enExample) |
| EA (1) | EA022470B1 (enExample) |
| ES (1) | ES2653847T3 (enExample) |
| IL (1) | IL227678B (enExample) |
| MA (1) | MA34909B1 (enExample) |
| MY (1) | MY162186A (enExample) |
| PE (1) | PE20141152A1 (enExample) |
| PH (1) | PH12013501528A1 (enExample) |
| PT (1) | PT2670765T (enExample) |
| SG (1) | SG192144A1 (enExample) |
| TN (1) | TN2013000321A1 (enExample) |
| TW (1) | TWI628188B (enExample) |
| UY (1) | UY33886A (enExample) |
| WO (1) | WO2012106190A1 (enExample) |
| ZA (1) | ZA201306546B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20182060T1 (hr) | 2008-04-18 | 2019-03-22 | Reata Pharmaceuticals, Inc. | Antioksidantni modulatori upale: derivati oleanolne kiseline s amino i drugim modifikacijama na c-17 |
| TW201006474A (en) | 2008-04-18 | 2010-02-16 | Reata Pharmaceuticals Inc | Natural products including an anti-flammatory pharmacore and methods of use |
| BRPI0911208B1 (pt) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals, Inc | Compostos moduladores inflamatórios antioxidantes, seu uso, e composição farmacêutica |
| ES2613964T3 (es) | 2008-04-18 | 2017-05-29 | Reata Pharmaceuticals, Inc. | Moduladores de inflamación antioxidantes: Derivados de ácido oleanólico homologado C-17 |
| AR084353A1 (es) | 2010-12-17 | 2013-05-08 | Reata Pharmaceuticals Inc | Enonas triciclicas de pirazolilo y pirimidinilo utiles como agentes antiinflamatorios y/o antioxidantes y composiciones farmaceuticas que las contienen |
| HUE026371T2 (en) * | 2011-01-31 | 2016-05-30 | Bristol Myers Squibb Co | C-28 amines from modified C-3 betulinic acid derivatives as anti-HIV matrices |
| PT2683731T (pt) | 2011-03-11 | 2019-07-12 | Reata Pharmaceuticals Inc | Derivados de triterpenóides c4-monometil e os métodos de utilização dos mesmos |
| EA023463B1 (ru) | 2011-09-21 | 2016-06-30 | Бристол-Майерс Сквибб Компани | Производные бетулиновой кислоты с противовирусной активностью |
| US8906889B2 (en) * | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| UA116209C2 (uk) | 2012-04-27 | 2018-02-26 | Ріта Фармасьютікалз, Інк. | 2,2-дифторпропіонамідні похідні бардоксолон-метилу, їхні поліморфні форми і способи застосування |
| US8889854B2 (en) * | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| AU2013304102B2 (en) * | 2012-08-15 | 2016-09-01 | Glaxo Group Limited | Chemical process |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| EA029174B1 (ru) | 2012-09-10 | 2018-02-28 | Рита Фармасьютикалз, Инк. | C17-алкандиильные и алкендиильные производные олеаноловой кислоты и способы их применения |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| BR112015018491A2 (pt) * | 2013-02-06 | 2017-07-18 | Bristol Myers Squibb Co | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv |
| EA027861B1 (ru) | 2013-02-25 | 2017-09-29 | Бристол-Майерс Сквибб Компани | C-3 алкил- и алкенилмодифицированные производные бетулиновой кислоты или их фармацевтические соли, противовирусная фармацевтическая композиция и фармацевтическая композиция для лечения вич на их основе |
| UA120927C2 (uk) | 2014-04-11 | 2020-03-10 | Віів Гелскер Юк (Но.4) Лімітед | Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл |
| US9920090B2 (en) | 2014-06-19 | 2018-03-20 | VIIV Healthcare UK (No.5) Limited | Betulinic acid derivatives with HIV maturation inhibitory activity |
| US10047118B2 (en) | 2014-11-14 | 2018-08-14 | VIIV Healthcare UK (No.5) Limited | C17-aryl substituted betulinic acid analogs |
| RU2017118489A (ru) | 2014-11-14 | 2018-12-14 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | Оксолупеновые производные |
| CN107428798A (zh) * | 2015-04-14 | 2017-12-01 | Viiv保健英国第四有限公司 | 生产hiv成熟抑制剂的方法 |
| KR20180028535A (ko) | 2015-07-28 | 2018-03-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체 |
| JP2018521093A (ja) | 2015-07-28 | 2018-08-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｈｉｖ感染を予防または治療するためのベツイン誘導体 |
| WO2017025901A1 (en) * | 2015-08-11 | 2017-02-16 | Hetero Research Foundation | Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors |
| EP3353190B1 (en) | 2015-09-23 | 2021-03-17 | Reata Pharmaceuticals, Inc. | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses |
| KR20180054826A (ko) | 2015-09-24 | 2018-05-24 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Hiv 성숙 억제 활성을 갖는 화합물 |
| BR112018010163A2 (pt) | 2015-11-20 | 2018-11-21 | Viiv Healthcare Uk No 4 Ltd | formulação, e, método para tratamento de infecção por hiv |
| AU2017208874A1 (en) * | 2016-01-20 | 2018-08-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Amine derivatives of lupanes with HIV maturation inhibitory activity |
| AR107512A1 (es) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| WO2018002849A1 (en) * | 2016-06-30 | 2018-01-04 | VIIV Healthcare UK (No.5) Limited | Triterpenoid inhibitors of human immunodeficiency virus replication |
| WO2018044822A1 (en) * | 2016-08-31 | 2018-03-08 | Viiv Healthcare Company | Combinations and uses and treatments thereof |
| BR112020002322A2 (pt) | 2017-08-04 | 2020-09-01 | Ardelyx, Inc. | derivados de ácido glicirretinínico para o tratamento de hipercalemia |
| JP6926939B2 (ja) * | 2017-10-23 | 2021-08-25 | 東京エレクトロン株式会社 | 半導体装置の製造方法 |
| JP6977474B2 (ja) * | 2017-10-23 | 2021-12-08 | 東京エレクトロン株式会社 | 半導体装置の製造方法 |
| US20210347813A1 (en) | 2018-04-24 | 2021-11-11 | Viiv Healthcare Uk (No. 5) Limited | Compounds with hiv maturation inhibitory activity |
| PL237998B1 (pl) | 2018-05-28 | 2021-06-28 | Narodowy Inst Lekow | Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| US11858959B2 (en) | 2019-02-07 | 2024-01-02 | Ardelyx, Inc. | Glycyrrhetinic acid derivatives for use in treating hyperkalemia |
| MY201070A (en) | 2019-02-11 | 2024-02-01 | Hetero Labs Ltd | Novel triterpene derivatives as hiv inhibitors |
| WO2021016191A1 (en) | 2019-07-19 | 2021-01-28 | Reata Pharmaceuticals, Inc. | C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof |
| GB2598300A (en) * | 2020-08-21 | 2022-03-02 | Univ Durham | Cross-linking method and applications in bioconjugation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5962527A (en) | 1995-03-21 | 1999-10-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating cancers |
| US5869535A (en) | 1995-03-21 | 1999-02-09 | The Board Of Trustees Of The University Of Illinois | Method and composition for selectively inhibiting melanoma |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| JP2007529544A (ja) | 2004-03-17 | 2007-10-25 | パナコス ファーマシューティカルズ， インコーポレイテッド | ３−ｏ−（３’，３’−ジメチルスクシニル）ベツリン酸の製薬的な塩 |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| US8067620B2 (en) | 2005-05-04 | 2011-11-29 | Medicines For Malaria Venture Mmv | Dispiro 1,2,4-trioxolane antimalarials |
| WO2008127364A2 (en) * | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
| US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| EP2257567A1 (en) * | 2008-02-14 | 2010-12-08 | Virochem Pharma Inc. | Novel 17 beta lupane derivatives |
| US9067966B2 (en) * | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| EP2576585B8 (en) * | 2010-06-04 | 2016-12-21 | VIIV Healthcare UK (No.5) Limited | Modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
| WO2011153319A1 (en) * | 2010-06-04 | 2011-12-08 | Bristol-Myers Squibb Company | C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
-
2012
- 2012-01-27 EP EP12702947.8A patent/EP2670765B1/en active Active
- 2012-01-27 JP JP2013551362A patent/JP6001560B2/ja active Active
- 2012-01-27 US US13/359,727 patent/US8846647B2/en active Active
- 2012-01-27 SG SG2013056858A patent/SG192144A1/en unknown
- 2012-01-27 MA MA36183A patent/MA34909B1/fr unknown
- 2012-01-27 PH PH1/2013/501528A patent/PH12013501528A1/en unknown
- 2012-01-27 MY MYPI2013701325A patent/MY162186A/en unknown
- 2012-01-27 CA CA2826113A patent/CA2826113C/en active Active
- 2012-01-27 ES ES12702947.8T patent/ES2653847T3/es active Active
- 2012-01-27 WO PCT/US2012/022852 patent/WO2012106190A1/en not_active Ceased
- 2012-01-27 AU AU2012212509A patent/AU2012212509B2/en active Active
- 2012-01-27 CN CN201280014966.XA patent/CN103429607B/zh active Active
- 2012-01-27 PE PE2013001719A patent/PE20141152A1/es active IP Right Grant
- 2012-01-27 KR KR1020137023070A patent/KR101886467B1/ko active Active
- 2012-01-27 EA EA201391127A patent/EA022470B1/ru not_active IP Right Cessation
- 2012-01-27 BR BR112013019419A patent/BR112013019419A2/pt not_active Application Discontinuation
- 2012-01-27 PT PT127029478T patent/PT2670765T/pt unknown
- 2012-01-31 UY UY0001033886A patent/UY33886A/es not_active Application Discontinuation
- 2012-01-31 AR ARP120100314A patent/AR085053A1/es unknown
- 2012-01-31 TW TW101103140A patent/TWI628188B/zh active
-
2013
- 2013-07-26 TN TNP2013000321A patent/TN2013000321A1/fr unknown
- 2013-07-28 IL IL227678A patent/IL227678B/en active IP Right Grant
- 2013-07-30 CL CL2013002185A patent/CL2013002185A1/es unknown
- 2013-08-27 CO CO13203030A patent/CO6751275A2/es unknown
- 2013-08-30 ZA ZA2013/06546A patent/ZA201306546B/en unknown
-
2014
- 2014-07-24 US US14/339,572 patent/US20140343000A1/en not_active Abandoned
-
2016
- 2016-02-04 US US15/015,741 patent/US20160151387A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503595A5 (enExample) | ||
| JP2014507422A5 (enExample) | ||
| JP2015510515A5 (enExample) | ||
| JP2013527243A5 (enExample) | ||
| JP2016509062A5 (enExample) | ||
| JP2016507558A5 (enExample) | ||
| HRP20151212T1 (hr) | C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P | |
| AR077435A1 (es) | Composiciones dermatologicas de antagonistas del receptor dp2 y uso | |
| JP2013507425A5 (enExample) | ||
| AR074165A1 (es) | Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas | |
| IL274901B2 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| MX372534B (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| JP2012524055A5 (enExample) | ||
| JP2017505314A5 (enExample) | ||
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| JP2015517976A5 (enExample) | ||
| EA201291301A1 (ru) | Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич | |
| SI3212174T1 (en) | Procedures for the treatment of infections with filoviridae virus | |
| RU2013116801A (ru) | Ингибиторы notum пектинацетилэстеразы и способы их применения | |
| HRP20130976T1 (hr) | Karbonilaminopirolopirazoli, potentni inhibitori kinaza | |
| JP2020532545A5 (enExample) | ||
| EA202090514A1 (ru) | Противовирусное средство против гепатита в | |
| RU2014122866A (ru) | Пропеноатные производные бетулина | |
| WO2012018534A3 (en) | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases | |
| RU2012157293A (ru) | Макроциклические соединения, применимые в качестве ингибиторов гистондеацетилаз |